SCHEMBL9362232

SCHEMBL9362232

CCCCCCCCCC(=O)N1CCC[C@H]1C(=O)O

nearest known ligand 0.57

Predicted protein targets (top 7)

geneUniProtsupporting neighboursconfidence
ACE P12821 7/20 0.57
ACE2 Q9BYF1 3/20 0.56
L3MBTL1 Q9Y468 2/20 0.50
REN P00797 1/20 0.49
GNAI3 P08754 1/20 0.48
GNAO1 P09471 1/20 0.48
GNAI1 P63096 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19024566 1.00 ACE (0.57) ACEACE2L3MBTL1RENGNAI3
SCHEMBL5035980 1.00 ACE (0.57) ACEACE2L3MBTL1RENGNAI3
SCHEMBL10757058 1.00 ACE (0.57) ACEACE2L3MBTL1RENGNAI3
SCHEMBL19024592 1.00 ACE (0.57) ACEACE2L3MBTL1RENGNAI3
SCHEMBL10537390 1.00 ACE (0.57) ACEACE2L3MBTL1RENGNAI3
SCHEMBL10406629 1.00 ACE (0.57) ACEACE2L3MBTL1RENGNAI3
SCHEMBL15650373 1.00 ACE (0.57) ACEACE2L3MBTL1RENGNAI3
SCHEMBL5035740 1.00 ACE (0.57) ACEACE2L3MBTL1RENGNAI3
SCHEMBL21853572 1.00 ACE (0.57) ACEACE2L3MBTL1RENGNAI3
SCHEMBL5035738 1.00 ACE (0.57) ACEACE2L3MBTL1RENGNAI3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 165 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3192493-B1 MOISTURIZER AND COSMETIC CONTAINING SAME AJINOMOTO KK (JP) 2023-07-12 EP claimed
EP-2870958-B1 MOISTURIZER AND COSMETIC CONTAINING SAME AJINOMOTO KK (JP) 2023-04-12 EP claimed
CN-115006266-A Formula, preparation method and application method of hydrogen-containing water nursing paste 深圳市巨印科技有限公司 2022-09-06 CN claimed
EP-3263093-B1 COSMETIC COMPOSITION AJINOMOTO KK (JP) 2022-07-20 EP claimed
US-20210087250-A1 PHARMACEUTICAL COMPOSITIONS FOR THE TRANSMUCOSAL DELIVERY OF THERAPEUTIC PEPTIDES AND PROTEINS CYPRUMED GMBH (AT) 2021-03-25 US claimed
EP-3006045-B3 Pharmaceutical formulations for the oral delivery of peptide or protein drugs CYPRUMED GMBH (AT) 2021-03-17 EP claimed
EP-3773475-A1 PHARMACEUTICAL COMPOSITIONS FOR THE TRANSMUCOSAL DELIVERY OF THERAPEUTIC PEPTIDES AND PROTEINS Cyprumed GmbH (AT) 2021-02-17 EP claimed
WO-2019193204-A1 PHARMACEUTICAL COMPOSITIONS FOR THE TRANSMUCOSAL DELIVERY OF THERAPEUTIC PEPTIDES AND PROTEINS CYPRUMED GMBH (AT) 2019-10-10 WO claimed
EP-3530711-A2 GEL COMPOSITION AJINOMOTO CO., INC. (JP) 2019-08-28 EP claimed
US-20190192404-A1 GEL COMPOSITION AJINOMOTO CO., INC. (JP) 2019-06-27 US claimed
EP-2870958-A1 MOISTURIZER AND COSMETIC CONTAINING SAME AJINOMOTO CO., INC. (JP) 2015-05-13 EP claimed
US-20150111859-A1 Moisturizer and Cosmetic Agent Containing Same AJINOMOTO CO., INC. (JP) 2015-04-23 US claimed
EP-2832345-A1 COSMETIC COMPOSITION Ajinomoto Co., Inc. (JP) 2015-02-04 EP claimed
US-20150010489-A1 COSMETIC COMPOSITION AJINOMOTO CO., INC. (JP) 2015-01-08 US claimed
US-20140056953-A1 FATTY ACID ACYLATED AMINO ACIDS FOR ORAL PEPTIDE DELIVERY NOVO NORDISK A/S (DK) 2014-02-27 US claimed
EP-2696847-A1 FATTY ACID ACYLATED AMINO ACIDS FOR ORAL PEPTIDE DELIVERY Novo Nordisk A/S (DK) 2014-02-19 EP claimed
WO-2012140155-A1 FATTY ACID ACYLATED AMINO ACIDS FOR ORAL PEPTIDE DELIVERY NOVO NORDISK A/S (DK) 2012-10-18 WO claimed
EP-0416282-B1 Microbiologically produced N-Acyl-L-proline-acylase, process for its production and its use DEGUSSA (DE) 1994-09-14 EP claimed
US-5219741-A Reacting in the presence of microbiologically produced N-acyl-L-proline acylase DEGUSSA AG (DE) 1993-06-15 US claimed
US-5120652-A Synthesis of proline from acyl derivatives; thermostable DEGUSSA AG (DE) 1992-06-09 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190192404-A1 GEL COMPOSITION BCAT1, BCAT2, AADAT ACE 2972/4885ACE2 2854/4885L3MBTL1 4069/4885
US-20150111859-A1 Moisturizer and Cosmetic Agent Containing Same FFAR1, PHOSPHO1, FAR1 ACE 2963/4885ACE2 3023/4885L3MBTL1 4755/4885
US-20210087250-A1 PHARMACEUTICAL COMPOSITIONS FOR THE TRANSMUCOSAL DELIVERY OF THERAPEUTIC PEPTIDES AND PROTEINS VIP, PTMS, VASP ACE 3715/4885ACE2 3285/4885L3MBTL1 4790/4885
US-20140056953-A1 FATTY ACID ACYLATED AMINO ACIDS FOR ORAL PEPTIDE DELIVERY SLC27A1, SLC27A2, FABP2 ACE 496/4885ACE2 613/4885L3MBTL1 4285/4885
US-20150010489-A1 COSMETIC COMPOSITION CUTA, TRPA1, MITF ACE 158/4885ACE2 447/4885L3MBTL1 4346/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.